Pacira BioSciences Announces $1.65 Billion Acquisition by Viatris
Shares of Pacira BioSciences surged over 40% on Thursday following the announcement that it has agreed to be acquired by Viatris for approximately $1.65 billion, or $36.50 per share. The deal represents a roughly 45% premium compared to Pacira's closing price from Wednesday and is expected to close by the end of 2026 after regulatory approvals. Viatris CEO Scott Smith highlighted that the acquisition will strengthen Viatris' position in non-opioid pain management, particularly through products like Exparel and Zilretta. The deal has been approved unanimously by both companies’ boards but is subject to customary closing conditions. This marks a significant development for Pacira BioSciences after years of stock volatility due to product portfolio changes and tepid growth. The acquisition offers mixed outcomes for shareholders: recent buyers are likely to profit, while long-term investors may see limited returns given the company's past performance.
Topics: acquisitions healthcare pharmaceuticals